Institute of Nano Science and Technology , Habitat Centre, Phase-10, Sector-64 , Mohali , Punjab - 160062 , India.
ACS Chem Neurosci. 2019 Mar 20;10(3):1157-1172. doi: 10.1021/acschemneuro.8b00652. Epub 2019 Feb 19.
Glioblastoma multiforme (GBM) is the most common and aggressive type of glial tumor, and despite many recent advances, its prognosis remains dismal. Hence, new therapeutic approaches for successful GBM treatment are urgently required. Magnetic hyperthermia-mediated cancer therapy (MHCT), which is based on heating the tumor tissues using magnetic nanoparticles on exposure to an alternating magnetic field (AMF), has shown promising results in the preclinical studies conducted so far. The aim of this Review is to evaluate the progression of MHCT for GBM treatment and to determine its effectiveness on the treatment either alone or in combination with other adjuvant therapies. The preclinical studies presented MHCT as an effective treatment module for the reduction of tumor cell growth and increase in survival of the tumor models used. Over the years, much research has been done to prove MHCT alone as the missing notch for successful GBM therapy. However, very few combinatorial studies have been reported. Some of the clinical studies carried out so far depicted that MHCT could be applied safely while possessing minimal side effects. Finally, we believe that, in the future, advancements in magnetic nanosystems might contribute toward establishing MHCT as a potential treatment tool for glioma therapy.
多形性胶质母细胞瘤(GBM)是最常见和侵袭性的神经胶质瘤,尽管最近有许多进展,但预后仍然很差。因此,迫切需要新的治疗方法来成功治疗 GBM。基于在交变磁场(AMF)暴露下使用磁性纳米粒子加热肿瘤组织的磁热疗(MHCT),在迄今为止进行的临床前研究中显示出了良好的效果。本综述的目的是评估 MHCT 治疗 GBM 的进展,并确定其单独或与其他辅助治疗联合使用的有效性。所呈现的临床前研究表明,MHCT 是减少肿瘤细胞生长和提高肿瘤模型存活率的有效治疗模块。多年来,已经进行了大量研究来证明 MHCT 本身是成功治疗 GBM 的缺失环节。然而,报道的组合研究很少。迄今为止进行的一些临床研究表明,MHCT 可以安全应用,同时具有最小的副作用。最后,我们相信,未来,磁性纳米系统的进步可能有助于将 MHCT 确立为治疗神经胶质瘤的潜在治疗工具。
ACS Chem Neurosci. 2019-2-19
Int J Nanomedicine. 2014-6-10
Int J Mol Sci. 2024-9-19
Int J Nanomedicine. 2011-3-25
Adv Drug Deliv Rev. 2018-11-7
Int J Mol Sci. 2024-9-19
Pharmaceuticals (Basel). 2024-2-26
Pharmaceutics. 2023-3-13